Clinical Research Directory
Browse clinical research sites, groups, and studies.
PD1 Inhibitors Combined With Clostridium Butyricum for Urothelial Carcinoma
Sponsor: The First Affiliated Hospital with Nanjing Medical University
Summary
This study intends to explore whether the combination of Clostridium butyricum can improve the current situation of poor anti-PD1 treatment effect in patients with bladder cancer.
Official title: Study on the Efficacy of Neoadjuvant or Adjuvant Therapy Based on PD1 Inhibitors Combined With Clostridium Butyricum Supplementation for Urothelial Carcinoma
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
60
Start Date
2024-02-01
Completion Date
2029-02-01
Last Updated
2024-11-20
Healthy Volunteers
No
Interventions
Clostridium Butyricum Tablets
Gemcitabine and Cisplatin combined with Clostridium Butyricum Tablets
Cisplatin
Gemcitabine and Cisplatin
Locations (1)
The First Affiliated Hospital of Nanjing Medical University
Nanjing, Jiangsu, China